How BEOVU May Help

BEOVU (brolucizumab-dbll) logo

Discover how
BEOVU may
help your vision

BEOVU (brolucizumab-dbll) logo

People experienced vision improvements with BEOVU

BEOVU was assessed in 2 clinical studies of 730 people with wet AMD. Both studies measured the mean change in best corrected visual acuity (ability to read letters on an eye chart) at year 1.

EDTRS eye chart EDTRS eye chart

Both studies also measured the percentage of people who maintained vision (defined as not losing 15 or more letters on an eye chart) at year 1.

93 maintained 93 maintained

BEOVU offers a 3-month dosing schedule in the first year of treatment

The recommended dose for BEOVU is 6 mg received by monthly injection for the first 3 treatments. Thereafter, BEOVU is given once every 2-3 months.

Over 50 Over 50

All others who received BEOVU were on a 2-month dosing
schedule.

Your doctor will determine the individual dosing schedule that's right for you

Find out how BEOVU works

Untreated wet AMD

Composite: inside wet amd eye/VEGF before TX

What is vascular endothelial growth factor?

Vascular endothelial growth factor (VEGF) is a protein responsible for producing new blood vessels. An excess amount of VEGF results in abnormal blood vessel growth.

What is wet AMD?

In an eye with wet AMD, abnormal blood vessels grow and leak fluid in the back of the eye. This can cause damage to the macula and lead to the loss of central vision.

Treated with BEOVU

Composite: inside wet amd eye/VEGF after TX

How does BEOVU work?

BEOVU blocks VEGF. This can help slow the growth of abnormal blood vessels that leak fluid into the macula.

Sign up to learn more about BEOVU.

Our records indicate that you have already registered for the program.

*Required fields

By clicking Submit, I agree that I am 18 years of age or older and I agree to the Novartis Pharmaceuticals Corporation Terms of Use. I understand and agree that the information I provide will be used in accordance with the Novartis Pharmaceuticals Corporation Privacy Policy, including to provide me with marketing information, offers, and promotions, and to contact me for my opinions regarding products, programs, and services. I understand that unless I unsubscribe by calling 1-888-669-6682 or clicking unsubscribe in a promotional e-mail, my consent will remain valid.

Submit

Text
Size

Contrast

Back to Top Back to Top

Expand

Close

INDICATION

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).

IMPORTANT SAFETY INFORMATION

You should not use BEOVU if you have an infection in or around the eye, eye inflammation, or if you are allergic to brolucizumab or any of the ingredients in BEOVU.

BEOVU is a prescription medicine given by injection into the eye. Injections in the eye, including BEOVU, may cause an infection of the eye or retinal detachment (separation of retina from the back of the eye). It is important to contact your doctor right away if your eye becomes red, sensitive to light, painful, or you develop a change in your vision.

Increased eye pressure has been seen within 30 minutes of an eye injection, including BEOVU. Sustained increases in eye pressure also have been reported. Your doctor should monitor for this when you receive a BEOVU injection.

There is a potential risk of stroke, heart attack, or blood clots in patients receiving eye injections of vascular endothelial growth factor (VEGF) inhibitor drugs, including BEOVU.

The most common side effects reported in patients receiving BEOVU were reduced clarity in vision, cataract, broken blood vessels in the eye, and vitreous floaters (moving spots in the field of vision).

You are encouraged to report negative side effects to FDA at www.fda.gov/medwatch or (800) FDA-1088.

Please see full Prescribing Information.

INDICATION

BEOVU® (brolucizumab-dbll) injection is used for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).